Focus: Insulet is a public medical device company specializing in insulin delivery systems, primarily the Omnipod platform for diabetes management. The company operates at ~300-500 employees with $1.7B in FY2025 revenue, positioning it as a dominant player in the automated insulin delivery market.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Hot — 296 jobs added in 30d
Net +102 (296 new, 194 removed). Aggressive expansion phase.
Insulet is a high-growth, profitable medical device company ideal for engineers and commercial talent seeking stability with strong visa sponsorship, but offers limited exposure to traditional drug development or early-stage discovery science.
Flagship closed-loop insulin delivery platform driving revenue growth and clinical adoption across both diabetes types.
Help build intelligence for Insulet
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Insulet's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Advanced automated glucose control system representing next-generation technology in Insulet's core diabetes franchise.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA(1c) (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial.
Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France?
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo